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Abstract
Historically, histomorphological and epidemiological data sugges-
ted that atypical ductal hyperplasia and ductal carcinoma in situ
are the earliest recognizable neoplastic stages of breast cancer
progression. Over the past several years, detailed high-throughput
molecular genetic, gene expression and epigenetic analyses have
enhanced our understanding of these early neoplastic lesions and
have re-shaped our view of human breast cancer progression to
include multiple distinct pathways of evolution.
Introduction
Atypical ductal hyperplasia (ADH) and ductal carcinoma in
situ (DCIS), the earliest neoplastic stages of human breast
cancer progression, are characterized by a proliferation of
epithelial cells that is confined within the basement membrane
of the mammary ductal network [1]. ADH and DCIS represent
a diverse group of tumors that are detected in women
undergoing screening mammography, and it is believed that
the detection of breast cancer in these early neoplastic stages
is largely responsible for the recent trend toward improvement
in breast cancer mortality worldwide. Historically, the
pathological distinction between ADH and DCIS is largely
morphological and is considered by some to be based upon
the size and extent of the epithelial proliferation [2]. The
classic model of breast cancer progression (Figure 1) is seen
as a linear multi-step process manifesting itself as a sequence
of pathologically defined stages in which molecular alterations
within normal breast epithelium give rise to ADH, the first
premalignant stage of breast cancer progression, upon which
progressive molecular alterations give rise to DCIS, the
second premalignant stage of breast cancer [3,4]. Additional
molecular alterations in DCIS are thought to give rise to the
malignant stages of invasive and metastatic carcinoma.
Until recently, a significant impediment to a better under-
standing of breast cancer progression has been our inability
to accurately interrogate the early neoplastic or premalignant
stages of this process. However, over the past several years
the successful application of combining highly specific tissue
microdissection technologies with advanced high-throughput
genomic and gene expression technologies has re-shaped
our view of breast cancer progression. Instead of viewing
breast cancer as a simple single linear pathway, recent
molecular genetic evidence supports a multiple linear
pathway model of progression.
Genomic analysis of premalignant breast
cancer
Loss of heterozygosity-based genomic studies of the pre-
malignant stages of breast cancer progression supported the
classic model of progression in which ADH and DCIS are
genetically related to each other and give rise to invasive
ductal carcinoma (IDC) [5-7]. However, the first significant
evidence suggesting that the classic model of breast cancer
progression required rethinking emerged from several
comparative genomic hybridization (CGH) studies of DCIS
and IDC [8]. Most notably, loss of 16q was seen almost
exclusively in low and intermediate grade DCIS, while a
higher frequency of 1q gain and 11q loss was observed in
intermediate grade DCIS [8]. High grade DCIS, on the other
hand, demonstrated complex genomic alterations that are
characterized by loss of 8p, 11q, 13q and 14q, by gains of
1q, 5p, 8q and 17q, and high-level amplifications of 17q12
and 11q13. Analysis of synchronous IDC associated with
DCIS revealed a near-identical genetic pattern supporting the
direct precursor relationship between DCIS and IDC.
Recently, Yao and colleagues [9], utilizing CGH in
conjunction with serial analysis of gene expression (SAGE),
have demonstrated an overall trend towards an increase in
the number and amplitude of gains and losses during breast
cancer progression, supporting the concept that the early
neoplastic stage of DCIS is a direct precursor to IDC.
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Together, these CGH-based studies continued to support
the classic linear model of progression (that is, ADH gives
rise to DCIS, which in turn gives rise to IDC), while providing
evidence that human breast cancer progression may consist
of several genetically distinct linear pathways that correlate
with histological tumor grade.
Gene expression analysis of ADH and DCIS
Over the past several years considerable research interest
has focused on understanding the gene expression changes
that occur during breast cancer development and, in
particular, during the early pre-invasive stage of progression
[10,11]. One of the earliest and most extensive studies is by
Ma and colleagues [10] in which patient-matched pheno-
typically normal breast epithelium from the terminal ductal
lobular unit and epithelium constituting ADH, DCIS and IDC
were microdissected and hybridized to a cDNA microarray
containing 12,000 genes. Comparative gene expression
profile analysis of patient-matched normal versus ADH,
normal versus DCIS, and normal versus IDC revealed that the
most pronounced transcriptome change occurred at the
normal to ADH transition, and that such transcriptional
alterations are maintained throughout the later stages (DCIS
and IDC) of progression. On a global level, no consistent
major transcriptional changes were identified between the
pre-invasive and invasive stages, and this observation was
consistent with SAGE data generated by Porter and
colleagues [11]. These data support the idea that the
different stages of breast cancer progression are evolutionary
products of the same clonal origin, and suggest that genes
expressed in the premalignant stages (ADH and DCIS) may
reflect the progressive potential of the pathological lesion.
The concept that gene expression of an early stage breast
cancer can predict future clinical behavior is well docu-
mented in the literature as it relates to early stage invasive
breast cancer and the risk of distant metastases [12-16].
Despite using different platforms (cDNA arrays versus
oligonucleotide arrays versus SAGE), several studies have
demonstrated that the transition from the premalignant stage
of DCIS to the malignant stage of IDC is associated with
quantitative, rather than qualitative, differences in gene
expression [10,11]. Intriguingly, this quantitative relationship
is most prominent in high grade (poorly differentiated/grade
III) samples, revealing an intriguing link between tumor grade
and tumor stage progression [10]. Similarly, the analysis of
breast cancer development in transgenic mouse models also
demonstrates that the transition from a pre-invasive to an
invasive stage of progression is associated with quantitative,
rather than qualitative, differences in gene expression [17]. All
of these observations taken together suggest that breast
cancer progression may be more complex than the current
linear theory of activation and inactivation of oncogenes and
tumor suppressor genes, respectively, and may be dependent
upon such contingencies as quantitative levels and timing of
gene expression.
Although distinct qualitative gene expression changes are not
observed during breast cancer stage progression, several
gene expression studies have demonstrated distinct expres-
sion alterations associated with different morphological
phenotypes and, in particular, tumor grade [10,18,19] . Low
grade (well differentiated/grade I) and high grade (poorly
differentiated/grade III) breast cancers have been demon-
strated to possess distinct reciprocal gene expression patterns
and these data are consistent with CGH data suggesting that
distinct gene expression pathways are associated with the
low grade and high grade phenotypes [10]. Not
unexpectedly, genes associated with the estrogen receptor
phenotype were prominently expressed in the low grade
DCIS, while genes associated with increased mitotic activity
and cell cycle processes were most commonly expressed in
cases of high grade DCIS [10]. Gene expression associated
with intermediate grade (moderately differentiated/grade II)
tumors exhibited a more complex pattern consisting of gene
expression elements associated with low and high grade
tumors. Using various class prediction algorithms, Ivshina and
colleagues [20] and Sotiriou and colleagues [19] have
identified gene expression indices that classify intermediate
grade tumors into low grade-like and high grade-like tumors
that display low and high risks of recurrence, respectively.
These latter studies highlight the imperfect nature of the
current histological grading system and, importantly, support
the view that low and high grade tumors reflect distinct
Figure 1
Classic linear multi-step model of human breast cancer progression based on histomorphological and epidemiological data. Molecular alterations
occurring in breast epithelium of a normal terminal duct lobular unit result in atypical ductal hyperplasia (ADH), the earliest neoplastic stage of
progression. Subsequent molecular alterations occur in ADH, resulting in ductal carcinoma in situ (DCIS), another early neoplastic stage, upon
which additional events occur, resulting in invasive ductal carcinoma (IDC).Page 3 of 4
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pathobiological entities rather than a direct continuum of
cancer progression, and that intermediate grade tumors likely
arise from these two distinct pathways [20].
An updated model of breast cancer progression
The development of breast cancer is a complex multi-step
process consisting of genetic and gene expression changes
that are frequently manifested in both the early (ADH and
DCIS) and late stages of progression. Based upon histo-
pathological observations as well as early genetic studies, a
simple model of breast cancer progression was proposed in
which the earliest neoplastic lesion, ADH, gives rise to low
grade DCIS that progresses to high grade DCIS, which
culminates in invasive carcinoma [4]. A number of recent
molecular-based studies support modification of this general
progression scheme. Firstly, and most importantly, CGH
based studies provide evidence of two distinct pathways in
the evolution of DCIS and IDC. One pathway is characterized
by 16q loss and is observed predominantly in low grade
tumors. The second pathway is characterized by 11q13 and
17q1 amplification. Interestingly, intermediate grade tumors
share genetic alterations common to either pathway,
suggesting that this population of tumors can arise from
either pathway. Secondly, results from several gene
Available online http://breast-cancer-research.com/content/10/1/302
Figure 2
Contemporary model of breast cancer progression based on genetic and gene expression data. Distinct molecular events occur in normal breast
epithelium giving rise to two divergent molecular pathways within which linear (denoted by vertical arrows) and horizontal (denoted by horizontal
arrows) progression occurs. The first pathway is characterized by genetic alterations that include gain of 1q and loss of 16q, and this pattern of
genetic alteration is seen predominantly in low grade ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) and in a subset (low
grade-like) of intermediate grade tumors. The second pathway is characterized by amplification of 11q13 and 17q12 in high grade tumors and
11q13 in a subset (high grade-like) of intermediate grade tumors. Additional support for the divergent two pathway model is provided by gene
expression profiling data (depicted as a gene expression heatmap) generated from atypical ductal hyperplasia (ADH), DCIS and IDC. More
specifically, low grade tumors express a unique set of genes that is rarely seen in high grade tumors and vice versa. Intermediate grade tumors
express either ‘low grade-like’ gene expression signatures or ‘high grade-like’ gene expression signatures.expression-based studies suggest that breast cancers are
stratified along two distinct gene expression pathways that
correlate directly with tumor grade. These results together
support a modified model of breast cancer progression
(Figure 2). Notably, this tumor grade-based stratification
scheme not only defines histopathological breast cancer
progression, but also breast cancer clinical outcome.
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